Browne, president and chief executive officer of Pharmacopeia Drug Discovery Inc., is presented. He offers a brief history of the company including its products and services. He discusses the reasons for the transformation of the company. He explains the key elements in redirecting or reorienting ...
This invention relates to the incorporation in compounds of sites that are substrates for phosphorylating enzymes. The compounds that are phosphorylated by these enzymes, for example proteins and peptides, are particularly useful in assays, such as those used in drug discovery. ...
Export Citation: Click for automatic bibliography generation Assignee: Pharmacopeia Drug Discovery Inc. (Princeton, NJ) Primary Class: 700/56 Other Classes: 422/65, 422/510, 700/57, 700/60, 700/61, 700/83 International Classes: G01N35/10;G01N35/00;G01N35/02; (IPC1-7): G05B19/18 ...
Pharmacopeia Announces Plan to Spin-Off Pharmacopeia Drug Discovery Business to StockholdersPharmacopeia, Inc. announced that its Board of Directors has approved a plan to separate its drug discovery and software businesses into two independent, publicly traded companies through the...
Pharmacopeia announces that proposed spin-off of Pharmacopeia Drug Discovery, Inc. unit is expectedtext editorEmerging Infectious Diseases
Reports on the outcome of the research collaboration between Pharmacopeia Drug Discovery Inc. and Celgene Corp. Objective of the research; Royalties which Pharmacopeia will be entitled from the eventual commercialization of the compounds discovered; Comments from Joseph A. Mollica, CEO and president of...
We highlight the similarities between the GWAS approach and well-established principles in early drug discovery, from primary screen through lead identification. We believe that integration of genetic and pharmacological screens will considerably enhance the development of therapeutic interventions with clear...
Reports on the plan of Pharmacopeia Inc. to spin off its drug discovery operation to stockholders, after which it will continue in the scientific software business under the name of its current software subsidiary, Accelrys Inc, in the U.S. Creation of two pure play companies that can better...
Daiichi, Pharmacopeia in pact.Report on Daiichi Pharmaceutical Corp.'s signing of an agreement with Pharmacopeia Inc., covering combinatorial chemistry and high throughput screening technology used in drug discovery.RotmanDavidEBSCO_AspChemical Week
will acquire the small-molecule drug discovery company Pharmacopeia Inc. According to Ligand chief executive officer John L. Ligands, the deal is a merge of biology and chemistry resources. It also notes that Pharmacopeia has cut its workforce in half to conserve cash and concentrate on later-...